Sacubitril/valsartan

Sacubitril/valsartan
Combination of
Sacubitril	Neprilysin inhibitor
Valsartan	Angiotensin II receptor antagonist
Clinical data
Trade names	Entresto, Azmarda, Neparvis, others
Other names	LCZ696
AHFS/Drugs.com	Monograph
MedlinePlus	a615039
License data	US DailyMed: Sacubitril and valsartan;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	C09DX04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	936623-90-4;
PubChem CID	71449007;
UNII	WB8FT61183;
KEGG	D10226;
CompTox Dashboard (EPA)	DTXSID50239500 ;
Chemical and physical data
Formula	C96H120N12Na6O21
Molar mass	1916.018 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+];
	InChI InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c21-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;21-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h26-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);24-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;51H2/q;;;;6+1;;;;;/p-6/t222-;217-,21+;;;;;;;;;;;/m0011.........../s1; Key:ZASXKEGREHRXDL-CAWNUZPDSA-H;

Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi). In 2016, the American College of Cardiology/American Heart Association Task Force recommended it as a replacement for an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction.

Potential side effects include angioedema, nephrotoxicity, and low blood pressure.

It was approved for medical use in the United States and in the European Union in 2015, and in Australia in 2016. In 2022, it was the 165th most commonly prescribed medication in the United States, with more than 3 million prescriptions. It is available as a generic medication.